MA54538A - Inhibiteurs d'apol1 et leurs procédés d'utilisation - Google Patents

Inhibiteurs d'apol1 et leurs procédés d'utilisation

Info

Publication number
MA54538A
MA54538A MA054538A MA54538A MA54538A MA 54538 A MA54538 A MA 54538A MA 054538 A MA054538 A MA 054538A MA 54538 A MA54538 A MA 54538A MA 54538 A MA54538 A MA 54538A
Authority
MA
Morocco
Prior art keywords
apol1
inhibitors
methods
apol1 inhibitors
Prior art date
Application number
MA054538A
Other languages
English (en)
Inventor
Michael Brodney
Jingrong Cao
Jon H Come
Leslie A Dakin
Francois Denis
Warren A Dorsch
Anne Fortier
Kevin Gagnon
Martine Hamel
Kan-Nian Hu
Elaine B Krueger
Brian Ledford
Ales Medek
Suganthini S Nanthakumar
Olivier Nicolas
Peter Rose
Camil Sayegh
Timothy J Senter
Yi Shi
Muna Shrestha
Tiansheng Wang
Faith Witkos
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of MA54538A publication Critical patent/MA54538A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0816—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring comprising Si as a ring atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/46—Phosphinous acids [R2POH], [R2P(= O)H]: Thiophosphinous acids including[R2PSH]; [R2P(=S)H]; Aminophosphines [R2PNH2]; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
MA054538A 2018-12-17 2019-12-17 Inhibiteurs d'apol1 et leurs procédés d'utilisation MA54538A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862780667P 2018-12-17 2018-12-17

Publications (1)

Publication Number Publication Date
MA54538A true MA54538A (fr) 2021-10-27

Family

ID=69182627

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054538A MA54538A (fr) 2018-12-17 2019-12-17 Inhibiteurs d'apol1 et leurs procédés d'utilisation

Country Status (24)

Country Link
US (3) US11618746B2 (fr)
EP (1) EP3897833A1 (fr)
JP (1) JP7573528B2 (fr)
KR (1) KR20210116483A (fr)
CN (1) CN113453760B (fr)
AR (1) AR116913A1 (fr)
AU (1) AU2019405477B2 (fr)
CA (1) CA3121910A1 (fr)
CL (1) CL2021001561A1 (fr)
CO (1) CO2021009053A2 (fr)
CR (1) CR20210383A (fr)
DO (1) DOP2021000116A (fr)
EC (1) ECSP21052184A (fr)
IL (2) IL283592B2 (fr)
JO (3) JOP20210131A1 (fr)
MA (1) MA54538A (fr)
MX (1) MX2021007152A (fr)
PE (1) PE20212302A1 (fr)
SA (1) SA521422270B1 (fr)
SG (1) SG11202105769XA (fr)
TW (1) TWI848031B (fr)
UA (1) UA128375C2 (fr)
UY (1) UY38514A (fr)
WO (1) WO2020131807A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618746B2 (en) 2018-12-17 2023-04-04 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
US12116343B2 (en) 2020-01-29 2024-10-15 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
TW202140459A (zh) * 2020-02-04 2021-11-01 美商維泰克斯製藥公司 Ａｐｏｌ１抑制劑之固體形式及其使用方法
TWI865738B (zh) * 2020-03-06 2024-12-11 美商維泰克斯製藥公司 治療apol-1依賴性局灶性節段性腎小球硬化之方法
EP4165022A1 (fr) * 2020-06-12 2023-04-19 Vertex Pharmaceuticals Incorporated Inhibiteurs d'apol1 et leur utilisation
CA3185144A1 (fr) * 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Inhibiteurs d'apol1 et leur utilisation
CA3183591A1 (fr) * 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Formes solides d'un inhibiteur d'apol1 et utilisation de celles-ci
MX2023002269A (es) 2020-08-26 2023-05-16 Vertex Pharma Inhibidores de apol1 y metodos para usar los mismos.
BR112023016631A2 (pt) * 2021-02-19 2023-11-14 Maze Therapeutics Inc Inibidores de apol1 e métodos de uso
JP2024532272A (ja) * 2021-08-26 2024-09-05 バーテックス ファーマシューティカルズ インコーポレイテッド 固体型のスピロ三環式ａｐｏｌ１阻害剤およびその使用方法
US20250084094A1 (en) * 2021-11-30 2025-03-13 Vertex Pharmaceuticals Incorporated Spirocyclic inhibitors of apol1 and methods of using same
IL314330A (en) 2022-01-18 2024-09-01 Maze Therapeutics Inc Apol1 inhibitors and methods of use
CA3251050A1 (fr) * 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated Dérivés de 2-méthyl-4',5'-dihydrospiro[pipéridine-4,7'-thiéno[2,3-c]pyran] utilisés en tant qu'inhibiteurs de apol1 et leurs procédés d'utilisation
WO2023194895A1 (fr) 2022-04-06 2023-10-12 Glaxosmithkline Intellectual Property Development Limited Dérivés pyrroliques utilisés en tant qu'inhibiteurs de l'apolipoprotéine l-1
EP4573077A1 (fr) * 2022-08-19 2025-06-25 Maze Therapeutics, Inc. Inhibiteurs d'apol1 et procédés d'utilisation
WO2025006262A1 (fr) * 2023-06-29 2025-01-02 Omniab, Inc. Composés tétracycliques contenant un indole fusionné pour le traitement d'une maladie rénale chronique médiée par apol1
GB202401326D0 (en) * 2024-02-01 2024-03-20 Podium Bio Ltd Novel compounds
KR20250122547A (ko) 2024-02-05 2025-08-14 서주사이언티픽 주식회사 AIoT 기반 방사성 동위원소 관리 시스템

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039676A (en) 1975-06-23 1977-08-02 Ciba-Geigy Corporation 2-piperidinoalkyl-1,4-benzodioxans
ZA977103B (en) 1996-08-09 1999-02-08 Eisai Co Ltd Benzopiperidine derivatives
ATE239013T1 (de) 1997-12-19 2003-05-15 Lilly Co Eli Hypoglykamische imidazoline derivate
GB9905010D0 (en) 1999-03-04 1999-04-28 Merck Sharp & Dohme Therapeutic agents
WO2001017965A2 (fr) 1999-09-07 2001-03-15 Syngenta Participations Ag Cyanopiperidines
FR2801585B1 (fr) 1999-11-25 2002-02-15 Fournier Ind & Sante Nouveaux antagonistes des recepteurs de l'ii-8
GB0003397D0 (en) 2000-02-14 2000-04-05 Merck Sharp & Dohme Therapeutic agents
EP1324985A4 (fr) 2000-10-02 2004-10-06 Merck & Co Inc Inhibiteurs de la prenyl-proteine transferase
FR2824827B1 (fr) 2001-05-17 2004-02-13 Fournier Lab Sa Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8
FR2824826B1 (fr) 2001-05-17 2003-11-07 Fournier Lab Sa Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8
AU2002360386A1 (en) 2001-11-14 2003-06-17 Teva Pharmaceutical Industries Ltd. Amorphous and crystalline forms of losartan potassium and process for their preparation
WO2003104180A1 (fr) * 2002-06-05 2003-12-18 Natco Pharma Limited Procede de preparation d'acide 4-(4-fluorobenzoyl) butyrique
ES2361924T3 (es) 2002-12-20 2011-06-24 X-Ceptor Therapeutics, Inc. Derivados de isoquinolinona y su uso como agentes terapéuticos.
JP2007504221A (ja) 2003-09-03 2007-03-01 ガラパゴス・エヌブイ 新規な４−ピペリジンカルボキシアミドおよび５ｈｔ２ａ受容体関連障害に対する薬剤の製造のためのその使用
EP1723105B1 (fr) 2004-03-03 2013-05-15 Eli Lilly And Company Modulateurs de recepteur nucleaire d'hormones steroides a base de derives indole substitues bicycliques
AR048523A1 (es) 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
EP1954276A2 (fr) 2005-11-22 2008-08-13 Merck & Co., Inc. Antagonistes des recepteurs de l'indole orexine
US8222288B2 (en) 2006-08-30 2012-07-17 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
WO2008046573A1 (fr) 2006-10-16 2008-04-24 Grünenthal GmbH Dérivés de sulfonamide substitués en tant que modulateurs du récepteur de bradykinine-1
CN101563324A (zh) 2006-12-22 2009-10-21 弗·哈夫曼-拉罗切有限公司 螺-哌啶衍生物
SI2118074T1 (sl) * 2007-02-01 2014-05-30 Resverlogix Corp. Spojine za preprečevanje in zdravljenje kardiovaskularnih bolezni
EP2020414A1 (fr) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. Derivés spiro[piperidine-4,4'-thieno[3,2-c]pyran] et composés similaires en tant que inhibiteurs du recepteur sigma pour le traitement de pyschose
KR20090018593A (ko) 2007-08-17 2009-02-20 주식회사 엘지생명과학 세포괴사 저해제로서의 인돌 및 인다졸 화합물
CN105254557A (zh) 2009-05-29 2016-01-20 拉夸里亚创药株式会社 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物
UA107943C2 (xx) 2009-11-16 2015-03-10 Lilly Co Eli Сполуки спіропіперидину як антагоністи рецептора orl-1
PT2501704E (pt) 2009-11-16 2013-12-05 Lilly Co Eli Compostos de espiropiperidina como antagonistas do receptor orl-1
WO2012025155A1 (fr) 2010-08-26 2012-03-01 Novartis Ag Composés à base d'hydroxamate en tant qu'inhibiteurs des désacétylases
BR102012024778A2 (pt) 2012-09-28 2014-08-19 Cristalia Prod Quimicos Farm Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
US10130632B2 (en) 2012-11-27 2018-11-20 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
EP3049405A4 (fr) 2013-09-26 2017-03-08 Pharmakea Inc. Composés inhibiteurs de l'autotaxine
EP3122726B1 (fr) 2014-03-27 2018-08-29 Academisch Medisch Centrum Iminosucres n-(5-((aryl ou hétéroaryl)méthyloxy)pentyl)-substitués comme inhibiteurs de glucosylcéramide synthase
CA2959437C (fr) 2014-08-27 2018-03-06 The Governing Council Of The University Of Toronto Modulateurs du recepteur cannabinoide de type 1
CN107001315A (zh) 2014-10-08 2017-08-01 国家健康与医学研究院 可用作蛋白质异戊二烯化的抑制剂的新型氨基吡啶化合物
CA2967097A1 (fr) 2014-11-21 2016-05-26 Laboratorios Del Dr. Esteve, S.A. Composes de spiro-isoquinoline-1,4'-piperidine a activite multimodale contre la douleur
WO2017033093A1 (fr) 2015-08-27 2017-03-02 Pfizer Inc. Composés hétéroaryle ou aryle bicycliques fusionnés en tant que modulateurs d'irak 4
JP6990657B2 (ja) 2016-02-08 2022-01-13 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｄｄｒ１阻害剤としてのスピロインドリノン
EP3787669A4 (fr) 2018-04-30 2022-03-30 The Trustees of Indiana University Composés destinés à moduler les niveaux de ddah et d'adma, ainsi que leurs méthodes d'utilisation pour traiter une maladie
JP7247227B2 (ja) 2018-05-22 2023-03-28 アイオニス・ファーマシューティカルズ・インコーポレイテッド Ａｐｏｌ１発現のモジュレーター
US11618746B2 (en) 2018-12-17 2023-04-04 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
US20220144838A1 (en) 2019-03-13 2022-05-12 Nanjing Immunophage Biotech Co., Ltd. Compounds as Inhibitors of Macrophage Migration Inhibitory Factor
CN115087440A (zh) 2019-12-19 2022-09-20 卡斯玛治疗公司 Trpml调节剂
US12116343B2 (en) 2020-01-29 2024-10-15 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
TW202140459A (zh) * 2020-02-04 2021-11-01 美商維泰克斯製藥公司 Ａｐｏｌ１抑制劑之固體形式及其使用方法
TWI865738B (zh) 2020-03-06 2024-12-11 美商維泰克斯製藥公司 治療apol-1依賴性局灶性節段性腎小球硬化之方法
CN115427404B (zh) 2020-04-22 2024-12-13 艾尼莫生物科技公司 胶原蛋白1翻译抑制剂和其使用方法
HUP2200468A1 (hu) 2020-04-29 2023-03-28 X Chem Zrt IAP antagonisták és gyógyászati alkalmazásuk
EP4146633A4 (fr) 2020-05-07 2024-09-25 Rambam Med-Tech Ltd. Composition destinée à être utilisée dans le traitement d'une maladie associée à apol1
EP4165022A1 (fr) 2020-06-12 2023-04-19 Vertex Pharmaceuticals Incorporated Inhibiteurs d'apol1 et leur utilisation
CA3183591A1 (fr) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Formes solides d'un inhibiteur d'apol1 et utilisation de celles-ci
CA3185144A1 (fr) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Inhibiteurs d'apol1 et leur utilisation
MX2023002269A (es) 2020-08-26 2023-05-16 Vertex Pharma Inhibidores de apol1 y metodos para usar los mismos.
JP2024532272A (ja) 2021-08-26 2024-09-05 バーテックス ファーマシューティカルズ インコーポレイテッド 固体型のスピロ三環式ａｐｏｌ１阻害剤およびその使用方法
US20250084094A1 (en) 2021-11-30 2025-03-13 Vertex Pharmaceuticals Incorporated Spirocyclic inhibitors of apol1 and methods of using same
US20230203000A1 (en) 2021-11-30 2023-06-29 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
US20250195483A1 (en) 2022-02-08 2025-06-19 Vertex Pharmaceuticals Incorporated Spiro piperidine derivatives as inhibitors of apol1 and methods of using same
JP2025505644A (ja) 2022-02-08 2025-02-28 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｐｏｌ１の阻害剤としての４’，５’－ジヒドロスピロ［ピペリジン－４，７’－チエノ［２，３－ｃ］ピラン］誘導体、及びそれを使用する方法
CA3251050A1 (fr) 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated Dérivés de 2-méthyl-4',5'-dihydrospiro[pipéridine-4,7'-thiéno[2,3-c]pyran] utilisés en tant qu'inhibiteurs de apol1 et leurs procédés d'utilisation
JP2025505200A (ja) 2022-02-08 2025-02-21 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｐｏｌ１の阻害剤としての２－メチル－４－フェニルピペリジン－４－オール誘導体、及びそれを使用する方法

Also Published As

Publication number Publication date
IL283592A (en) 2021-07-29
KR20210116483A (ko) 2021-09-27
JP7573528B2 (ja) 2024-10-25
AR116913A1 (es) 2021-06-23
WO2020131807A1 (fr) 2020-06-25
US12060346B2 (en) 2024-08-13
DOP2021000116A (es) 2021-09-30
IL283592B2 (en) 2025-08-01
UY38514A (es) 2020-07-31
JOP20210130A1 (ar) 2023-01-30
CN113453760A (zh) 2021-09-28
EP3897833A1 (fr) 2021-10-27
CO2021009053A2 (es) 2021-08-09
TW202039471A (zh) 2020-11-01
TWI848031B (zh) 2024-07-11
AU2019405477A1 (en) 2021-06-24
MX2021007152A (es) 2021-11-03
SG11202105769XA (en) 2021-07-29
CL2021001561A1 (es) 2021-11-26
ECSP21052184A (es) 2021-08-31
AU2019405477B2 (en) 2025-04-03
US20230271945A1 (en) 2023-08-31
US11618746B2 (en) 2023-04-04
IL319575A (en) 2025-05-01
CA3121910A1 (fr) 2020-06-25
JOP20210131A1 (ar) 2023-01-30
PE20212302A1 (es) 2021-12-10
SA521422270B1 (ar) 2024-02-18
US20250042878A1 (en) 2025-02-06
JOP20210129A1 (ar) 2023-01-30
IL283592B1 (en) 2025-04-01
US20200377479A1 (en) 2020-12-03
JP2022515369A (ja) 2022-02-18
BR112021011564A2 (pt) 2021-08-31
CN113453760B (zh) 2024-05-24
CR20210383A (es) 2021-09-22
UA128375C2 (uk) 2024-06-26

Similar Documents

Publication Publication Date Title
MA54538A (fr) Inhibiteurs d'apol1 et leurs procédés d'utilisation
EP3911648A4 (fr) Inhibiteurs de pcsk9 et leurs procédés d'utilisation
EP3968999A4 (fr) Inhibiteurs de fgfr et leurs procédés d'utilisation
MA55136A (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
MA54758A (fr) Inhibiteurs de pcsk9 et leurs procédés d'utilisation
EP3946329A4 (fr) Agonistes bêta-adrénergique et leurs procédés d'utilisation
EP3846808A4 (fr) Inhibiteurs de papd5 et leurs procédés d'utilisation
EP3775203A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
MA55885A (fr) Chélateurs macrocycliques et leurs procédés d'utilisation
EP3962481A4 (fr) Inhibiteurs de kcnt1 et procédés d'utilisation
EP3684364A4 (fr) Pyridazinones et leurs procédés d'utilisation
MA51837A (fr) Inhibiteurs de l'arginase et leurs procédés d'utilisation
MA71645A (fr) Pyridazinones et leurs procédés d'utilisation
EP3765006A4 (fr) Inhibiteurs d'arginase et procédés d'utilisation
EP3710430A4 (fr) Inhibiteurs d'acss2 et leurs procédés d'utilisation
MA52797A (fr) Inhibiteurs de masp -2 et procédés d'utilisation
EP3810615A4 (fr) Inhibiteurs d'arginase et procédés d'utilisation
MA55381A (fr) Pyridazinones et leurs procédés d'utilisation
EP4034605A4 (fr) Compositions de polissage et leurs procédés d'utilisation
EP4031144A4 (fr) Benzimidazoles et leurs procédés d'utilisation
EP3717504A4 (fr) Inhibiteurs de yeats et leurs procédés d'utilisation
EP3806834A4 (fr) Clamps dynamiques et leurs procédés d'utilisation
EP4045226A4 (fr) Compositions de polissage et leurs procédés d'utilisation
EP3947351A4 (fr) Inhibiteurs de parg à petites molécules et leurs procédés d'utilisation
EP3463366A4 (fr) Formulations topiques d'inhibiteurs de pde-4 et leurs procédés d'utilisation